Evidence map›Paper›PMID 33396632›Full record

ArticlePharmaceuticals (Basel, Switzerland)2020

NLRP1 Functions Downstream of the MAPK/ERK Signaling via ATF4 and Contributes to Acquired Targeted Therapy Resistance in Human Metastatic Melanoma.

Zili Zhai, Prasanna K Vaddi, Jenny Mae Samson, Tomoya Takegami, Mayumi Fujita

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. DownregulatedCells · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Zili ZhaiDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Prasanna K VaddiDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Jenny Mae SamsonDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Tomoya TakegamiDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Mayumi FujitaDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-1498-1925
University of Colorado Anschutz Medical Campus · USVA Eastern Colorado Health Care System · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Transgenic and Gene Targeting CoreP30AR057212 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI HOGAN, CHRISTOPHER J · 2009 to 2018
$6.2M
Modulation of Inflammasome-mediated cytokine activation by EGCG in human melanomaR01CA197919 · NCI · UNIVERSITY OF COLORADO DENVER · PI FUJITA, MAYUMI · 2016 to 2020
$1.9M
Autoinflammation in Human MelanomaI01BX001228 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI FUJITA, MAYUMI · 2012 to 2022
–
BLRD VA I01 BX001228NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA197919NIAMS NIH HHS P30 AR057212NIH HHS R01 CA197919Veterans Affairs Merit Review Award 5I01BX001228
6 · The paper itself

Abstract

The

Indexed as

ATF4melanomaNLRP1resistancetargeted therapy

Identifiers

PMID33396632
PMCPMC7823742
OpenAlexW3116880962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.